RPI-1 Catalog No.:M16910-C and inhibits RANKL-mediated MAPK and

and inhibits RANKL-mediated MAPK and NF-κB signaling pathway in osteoclasts

InChi: InChI=1S/C16H14O6/c1-22-16-9(3-7-13(19)15(16)21)2-5-11(17)10-4-6-12(18)14(20)8-10/h2-8

LY2409881 potently synergizes with histone deacetylase inhibitors in preclinical models of lymphoma through the downregulation of NF-κB

Zimmerman D

RPI-1 Catalog No.:M16910-C and inhibits RANKL-mediated MAPK andRPI 1 is a specific, orally available 2 indolinone Ret tyrosine kinase inhibitor. RPI 1 inhibits proliferation, Ret tyrosine phosphorylation, Ret protein expression, and the activation of PLCgamma, ERKs and AKT in human medullary thyroid carcinoma TT cells. Antitumor activity. Product information CAS Number: 269730 03 2 Molecular Weight: 297. 31 Formula: C17H15NO4 Chemical Name: (3Z) 3 [(4 hydroxyphenyl)methylidene] 5,6 dimethoxy 2,3 dihydro 1H indol